Abstract
Chronic myelogenous leukemia, BCR-ABL1+ (CML) is a myeloproliferative neoplasm characterized by a BCRABL fusion gene and almost always exhibits the characteristic cytogenetic finding t(9;22)(q34;q11). The protein product of BCR-ABL1 is a constitutively active tyrosine kinase whose function is intrinsic to CML pathogenesis. Patients present with leukocytosis and often splenomegaly and prominent marrow hypercellularity with marked myeloid hyperplasia and basophilia in most cases. Unlike acute leukemias, the neoplastic myeloid cells in CML exhibit a full spectrum of maturation at the early stages of disease, but if untreated CML inexorably progresses to an acute leukemia. The recent development BCR-ABL1 tyrosine-kinase inhibitors has profoundly changed the clinical course of patients with CML; most patients achieve long-term remissions if they are treated in the early part of the disease course. Monitoring of resistance to tyrosine-kinase inhibitors and assessment for disease progression are critical in current CML management. Therapeutic approaches, including targeted therapy, is discussed.
Keywords: Chronic myelogenous leukemia, chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL, imatinib, tyrosine kinase inhibitors, myeloproliferative neoplasms
Current Cancer Therapy Reviews
Title: Chronic Myelogenous Leukemia
Volume: 8 Issue: 1
Author(s): Robert P. Hasserjian
Affiliation:
Keywords: Chronic myelogenous leukemia, chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL, imatinib, tyrosine kinase inhibitors, myeloproliferative neoplasms
Abstract: Chronic myelogenous leukemia, BCR-ABL1+ (CML) is a myeloproliferative neoplasm characterized by a BCRABL fusion gene and almost always exhibits the characteristic cytogenetic finding t(9;22)(q34;q11). The protein product of BCR-ABL1 is a constitutively active tyrosine kinase whose function is intrinsic to CML pathogenesis. Patients present with leukocytosis and often splenomegaly and prominent marrow hypercellularity with marked myeloid hyperplasia and basophilia in most cases. Unlike acute leukemias, the neoplastic myeloid cells in CML exhibit a full spectrum of maturation at the early stages of disease, but if untreated CML inexorably progresses to an acute leukemia. The recent development BCR-ABL1 tyrosine-kinase inhibitors has profoundly changed the clinical course of patients with CML; most patients achieve long-term remissions if they are treated in the early part of the disease course. Monitoring of resistance to tyrosine-kinase inhibitors and assessment for disease progression are critical in current CML management. Therapeutic approaches, including targeted therapy, is discussed.
Export Options
About this article
Cite this article as:
P. Hasserjian Robert, Chronic Myelogenous Leukemia, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462486
DOI https://dx.doi.org/10.2174/157339412799462486 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Matrix Metalloproteinases
Current Medicinal Chemistry Ciprofloxacin Stress Proteome of the Extended-Spectrum β-lactamase Producing Escherichia coli from Slaughtered Pigs
Current Proteomics Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry Anticancer Perspectives on the Fungal-Derived Polyphenolic Hispolon
Anti-Cancer Agents in Medicinal Chemistry Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design DNA Intercalators in Cancer Therapy: Organic and Inorganic Drugs and Their Spectroscopic Tools of Analysis
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Organic Synthesis Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Hybrid Pharmacophore Design and Synthesis of Naphthalimide– Benzimidazole Conjugates as Potential Anticancer Agents
Letters in Drug Design & Discovery The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism